From Payload to Patient: Advanced Approaches to HER2, TROP2, and B7-H3 Antibody-Drug Conjugate (ADC) Safety

This activity was originally presented at the 2026 HOPA Annual Conference in New Orleans, LA.

Antibody-drug conjugates (ADCs) have rapidly transformed the treatment landscape for multiple solid tumors, including breast, lung, urothelial, and gynecologic malignancies. While ADCs offer targeted advantages, incorporating them into complex treatment regimens presents significant clinical challenges. As the number of ADC approvals increases, so does concern regarding toxicity attribution, particularly in combination regimens where it is difficult to distinguish whether an adverse event is driven by the ADC's payload, its target-mediated "off-tumor" effects, or a concomitant agent. This session will explore the tripartite structure of ADCs and how these components influence both therapeutic efficacy and distinct toxicity profiles. The pharmacist's role in reducing clinical uncertainty by implementing evidence-based monitoring, constructing prophylactic protocols, and leading interdisciplinary coordination will be emphasized. The included case-based discussions will address concepts ranging from the application of adverse event grading and dose modification criteria to toxicity prevention and patient counseling for delayed or home-based toxicities.

Target audience: Oncology pharmacists

Type of activity: Application

Release date: April 15, 2026

Expiration date: April 15, 2027

Learner level: Advanced

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply Common Terminology Criteria for Adverse Events-based grading and prescribing information guidance to differentiate and manage antibody-drug conjugate (ADC)-related toxicities in combination regimens
• Factor evidence-based monitoring and intervention strategies for ADC-specific toxicities into patient care workflows to ensure early detection, timely escalation, and improved patient safety
• Construct practical supportive care protocols and counseling frameworks for patients receiving ADC therapy, including prophylactic measures, coordination of care, and patient education on toxicity prevention and red-flag symptoms
  

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-064-H05-P. The activity is available for CE credit through April 15, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Stefanie Houseknecht, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Daiichi Sankyo

Stock: Pfizer

Megan May, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Amgen, AstraZeneca

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Matthew J. Hadfield, DO

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:

ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:

www.pharmacytimes.org/terms